Reuters (4/19, Ajmera) reported the FDA on Friday granted approval for generic drugmaker Teva Pharmaceutical Industries “to market its generic nasal spray for opioid overdose,” marking “the first approval of a generic naloxone nasal spray for use in a community setting by individuals without medical training.”
The AP (4/19, Johnson) wrote, “Naloxone has been sold as a nasal spray in the U.S. since 2016 under the brand name Narcan.” The AP highlighted that “pharmacists can dispense it without a prescription. It is also sold as a generic or brand-name drug in automatic injectors, prefilled syringes and vials.”
Related Links:
— “FDA approves Teva’s generic nasal spray to treat opioid overdose, “Ankit Ajmera, Reuters, April 19, 2019